Anemia is a frequent condition in patients with chronic kidney disease due to a reduction in the production of erythropoietin. Patients with inflammation respond less well to treatment with erythropoietin, possibly because the increased production of hepcidin reduces the availability of iron for hematopoiesis. Some studies suggest that pentoxifylline has anti-inflammatory properties and could be used as adjuvant therapy in the treatment of anemia.
Objective
The aim of this study was to analyze the effect of pentoxifylline on serum hepcidin in chronic hemodialysis patients with inflammation.
Methods
71 adult patients on hemodialysis with C-reactive protein (CRP) ≥0.5 mg/dl in screening tests; patients were randomized to the treatment group (oral pentoxifylline 400 mg/thrice-weekly) or the control group for 3 months follow-up.
Results
During the study, a decrease in hemoglobin, transferrin saturation, and hepcidin was observed in both groups. However, these reductions were related to the time and not to the drug. There was no difference in the concentrations of CRP, ferritin, and albumin over time in either group.
Conclusions
The use of this amount of pentoxifylline did not modify the serum levels of hepcidin in this population.
AbreuP.F., Romão JuniorJ.E., BastosM.G.. Use of erythropoiesis stimulating agents.J Bras Nefrol.2014; 36(1 Suppl 1): 19–23.
2.
van der WeerdN.C., GrootemanM.P.C., BotsM.L.; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.PLoS One.2012; 7(7): e39783.
3.
NicolasG., ChauvetC., ViatteL.. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.J Clin Invest.2002; 110(7): 1037–1044.
4.
D'HellencourtC.L., DiawL., CornilletP., GuenounouM.. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline.Int J Immunopharmacol.1996; 18(12): 739–748.
5.
González-EspinozaL., Rojas-CamposE., Medina-PérezM., Peña-QuinteroP., Gómez-NavarroB., Cueto-ManzanoA.M.. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial.Nephrol Dial Transplant.2012; 27(5): 2023–2028.
6.
CooperA., MikhailA., LethbridgeM.W., KemenyD.M., MacdougallI.C.. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure.J Am Soc Nephrol.2004; 15(7): 1877–1882.
7.
NavarroJ.F., MoraC., GarcíaJ.. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure.Scand J Urol Nephrol.1999; 33(2): 121–125.
8.
FerrariP., MallonD., TrinderD., OlynykJ.K.. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.Nephrology (Carlton).2010; 15(3): 344–349.
9.
MacdougallI.C., MalyszkoJ., HiderR.C., BansalS.S.. Current status of the measurement of blood hepcidin levels in chronic kidney disease.Clin J Am Soc Nephrol.2010; 5(9): 1681–1689.
10.
AshbyD.R., GaleD.P., BusbridgeM.. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.Kidney Int.2009; 75(9): 976–981.
11.
ZaritskyJ., YoungB., WangH.J.. Hepcidin—a potential novel biomarker for iron status in chronic kidney disease.Clin J Am Soc Nephrol.2009; 4(6): 1051–1056.
12.
TomosugiN., KawabataH., WakatabeR.. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System.Blood.2006; 108(4): 1381–1387.
KatoA., TsujiT., LuoJ., SakaoY., YasudaH., HishidaA.. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.Am J Nephrol.2008; 28(1): 115–121.
15.
PetersH.P.E., LaarakkersC.M.M., SwinkelsD.W., WetzelsJ.F.M.. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate.Nephrol Dial Transplant.2010; 25(3): 848–853.
16.
WeissG., TheurlI., EderS.. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.Eur J Clin Invest.2009; 39(10): 883–890.
17.
UehataT., TomosugiN., ShojiT.. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.Nephrol Dial Transplant.2012; 27(3): 1076–1083.
18.
CoyneD.W.. Hepcidin: clinical utility as a diagnostic tool and therapeutic target.Kidney Int.2011; 80(3): 240–244.
19.
CourselaudB., TroadecM.B., FruchonS.. Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice.Blood Cells Mol Dis.2004; 32(2): 283–289.
20.
IkedaY., TajimaS., Izawa-IshizawaY.. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes.PLoS One.2012; 7(7): e40465.
21.
ItkonenO., ParkkinenJ., StenmanU.H., HämäläinenE.. Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method.Clin Chim Acta.2012; 413(7-8): 696–701.
22.
KemnaE., PickkersP., NemethE., van der HoevenH., SwinkelsD.. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.Blood.2005; 106(5): 1864–1866.
23.
PasrichaS-R, McQuiltenZ., WestermanM.. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors.Haematologica.2011; 96(8): 1099–1105.
24.
NemethE., RiveraS., GabayanV.. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.J Clin Invest.2004; 113(9): 1271–1276.
25.
StenvinkelP.. Anaemia and inflammation: what are the implications for the nephrologist?Nephrol Dial Transplant.2003; 18(8)(Suppl 8): viii17–22.
26.
Tussing-HumphreysL., PusatciogluC., NemethE., BraunschweigC.. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin.J Acad Nutr Diet.2012; 112(3): 391–400.
27.
SarafidisP.A., RumjonA., MacLaughlinH.L., MacdougallI.C.. Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin.Nephrol Dial Transplant.2012; 27(1): 50–57.
28.
Mora-GutiérrezJ.M., Ferrer-NadalA., García-FernándezN.. Effect of pentoxifylline on anaemia control in haemodialysis patients: retrospective observational case-control study.Nefrologia.2013; 33(4): 524–531.
29.
AntunesS.A., TeixeiraM.C.B., JuniorA.G.. Efeitos da pentoxifilina na anemia resistente à eritropoetina em pacientes sob hemodiálise.[Pentoxifylline effects on the resistant anemia to erythropoietin in hemodialysis patients] [Article in Portughese] Rev Bras Hematol Hemoter.2008; 30(4): 303–308.
30.
MeuweseC.L., StenvinkelP., DekkerF.W., CarreroJ.J.. Monitoring of inflammation in patients on dialysis: forewarned is forearmed.Nat Rev Nephrol.2011; 7(3): 166–176.
